Researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Walter Reed Army Medical Center evaluated metastasis-free survival (MFS) and overall survival (OS) among men with a biochemical reoccurrence (PSA only) of prostate cancer after having received a radical prostatectomy but did not receive additional therapy until developing metastases […]
A PSA only recurrence (biochemical failure) post a primary treatment for prostate cancer is relatively common, approximately 30% of those treated! A biochemical failure is characterized a return of increasing PSA without any other evidence of cancer on a scan. Failure can happen immediately after primary treatment has been completed or many years after the [...]
There is a brief, but great YouTube video that very simply and clearly explains the current thinking about how and why prostate cancer becomes androgen independent (castrate resistant). View the video by clicking here Joel T Nowak, M.A., M.S.W.
To evaluate the effects of timing and length of zoledronic acid (ZA) treatment on outcomes for men with prostate cancer, researchers from the University of Illinois at Chicago and the Hind T. Hatoum & Company, Chicago, IL. evaluated a large contingent of men who had been diagnosed with prostate cancer from January 2003 to October [...]
Applications for the approval of Abiraterone Acetate (Abiraterone) have been submitted to both the U.S. Food and Drug Administration (FDA) and to the European Medicines Agency (EMA). The applications are for the approval of Abiraterone with prednisone for the treatment of metastatic advanced prostate cancer in men who have received prior chemotherapy containing a taxane. [...]